Mereo BioPharma Group plc - ADR (MREO) stock is lower by -88.69% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives MREO stock a score of 21 out of a possible 100.
That rank is chiefly influenced by a long-term technical score of 1. MREO's rank also includes a short-term technical score of 2. The fundamental score for MREO is 61. In addition to the average rating from Wall Street analysts, MREO stock has a mean target price of $8.00. This means analysts expect the stock to climb 2062.16% over the next 12 months. MREO has an Overall Score of 21. Find out what this means to you and get the rest of the rankings on MREO!